Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maryse Lapeyre-Mestre

Showing results (1-10 of 314) with videos related to

Pageof 32
Sort By:
Therapie|March 14, 2020
The challenges of pharmacoepidemiology of orphan drugs in rare diseasesMaryse Lapeyre-Mestre
Therapie|October 20, 2018
[Benzodiazepines, cognitive decline and dementia: A review of causality criteria from published observational studies]Maryse Lapeyre-Mestre
Therapie|October 24, 2022
Addictovigilance in women, the hidden part of the iceberg?Maryse Lapeyre-Mestre
Drugs & Aging|November 5, 2016
A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with DementiaMaryse Lapeyre-Mestre
Expert Opinion on Drug Safety|April 7, 2010
Safety of amide local anesthetics: new trendsRegis Fuzier, Maryse Lapeyre-Mestre
Drug Safety|March 9, 2007
Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP surveyOlivia Boeuf, Maryse Lapeyre-Mestre,
Therapie|April 11, 2015
Drug abuse monitoring: which pharmacoepidemiological resources at the European level?Maryse Lapeyre-Mestre, Mathilde Dupui
Therapie|May 2, 2017
[Psychoactive effects of 'legal high': About lysergic acid amide (LSA)]Camille Ponté, Maryse Lapeyre-Mestre
Therapie|February 23, 2019
Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugsMaryse Lapeyre-Mestre, François Montastruc
Therapie|December 23, 2009
Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs?Joëlle Micallef-Roll, Maryse Lapeyre-Mestre,
Pageof 32

Showing results (1-10 of 314) with videos related to

Sort By:
Pageof 32
Therapie|March 14, 2020
The challenges of pharmacoepidemiology of orphan drugs in rare diseasesMaryse Lapeyre-Mestre
Therapie|October 20, 2018
[Benzodiazepines, cognitive decline and dementia: A review of causality criteria from published observational studies]Maryse Lapeyre-Mestre
Therapie|October 24, 2022
Addictovigilance in women, the hidden part of the iceberg?Maryse Lapeyre-Mestre
Drugs & Aging|November 5, 2016
A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with DementiaMaryse Lapeyre-Mestre
Expert Opinion on Drug Safety|April 7, 2010
Safety of amide local anesthetics: new trendsRegis Fuzier, Maryse Lapeyre-Mestre
Drug Safety|March 9, 2007
Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP surveyOlivia Boeuf, Maryse Lapeyre-Mestre,
Therapie|April 11, 2015
Drug abuse monitoring: which pharmacoepidemiological resources at the European level?Maryse Lapeyre-Mestre, Mathilde Dupui
Therapie|May 2, 2017
[Psychoactive effects of 'legal high': About lysergic acid amide (LSA)]Camille Ponté, Maryse Lapeyre-Mestre
Therapie|February 23, 2019
Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugsMaryse Lapeyre-Mestre, François Montastruc
Therapie|December 23, 2009
Second meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs?Joëlle Micallef-Roll, Maryse Lapeyre-Mestre,
Pageof 32